Summary
This document is a technical report that outlines the use of Dovato (dolutegravir/lamivudine) in real-world settings based on a growing body of evidence from over 41,000 patients. It presents data from systematic literature reviews identifying people living with HIV who received Dovato as a two-drug regimen. The report documents high rates of virologic effectiveness consistent with Phase 3 trials, including GEMINI-1, GEMINI-2, TANGO, and SALSA, with low discontinuation rates due to adverse events. It highlights results from various cohorts, detailing effectiveness outcomes for treatment-naïve and treatment-experienced patients. Notably, 19 virologic failures were reported in treatment-naïve cohorts, and resistance-associated mutations were rare. The report further summarizes meta-analysis findings that confirm sustained virologic suppression and low rates of virologic failure over extended follow-up periods. It includes important safety information and directs readers to consult prescribing information for further details.
